<DOC>
	<DOCNO>NCT01640574</DOCNO>
	<brief_summary>In Southeast Asia , Plasmodium vivax ( Pv ) infection reach 50-80 % bear great burden disease Plasmodium falciparum ( Pf ) . As control Pf improve , Pv assume increasingly large percentage malaria prevalence . The chronicity Pv , due latent liver stage ( hypnozoite ) eradicate chloroquine , cause recur disability compound economic burden symptomatic disease . The widely available treatment hypnozoites primaquine , , challenge tolerability , safety G6PD deficient person , compliance , commonly prescribe treatment Pv . Currently , chloroquine use treatment blood stage Pv , however , concern increase parasite resistance . Alternative treatment , artesunate , consider future treatment blood stage Pv . The use primaquine treatment hypnozoites ( radical cure ) emphasize transmission Pv control . This study aim determine optimal primaquine regimen radical cure Plasmodium vivax . Chloroquine currently standard treatment Plasmodium vivax . Chloroquine may synergistic effect use primaquine due long half-life may delay first relapse vivax malaria . In contrast , artesunate document interaction primaquine short half-life , thus , presumably impact first relapse . Combining primaquine two anti-malarials may lead alternative regimen Pv infection change primaquine dose regimen may lead practical efficacious therapy .</brief_summary>
	<brief_title>Comparison Between 7 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine 3 Day Chloroquine Radical Cure P. Vivax ( BPD )</brief_title>
	<detailed_description />
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>≥ 6 month old Microscopic diagnosis Plasmodium vivax malaria monoinfection Participant parent/guardian willing able give inform consent participation study Able ( Investigators opinion ) willing comply study requirement . Severe malaria History allergy adverse reaction artesunate , piperaquine , chloroquine , primaquine Blood transfusion past 3 month G6PD deficiency rapid test Hematocrit ≤ 25 % Pregnancy time screen Breastfeeding infant &lt; 6 month old Presence condition judgement investigator would place subject undue risk interfere result study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vivax</keyword>
	<keyword>Chloroquine</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Dihydroartemisinin-Piperaquine</keyword>
</DOC>